In this week’s VJOncology podcast, we are joined by Javier Martín-Broto, MD, PhD, Fundación Jiménez Díaz University Hospital, Madrid, Spain, who shares expert insights on the evolving role of immunotherapy in sarcoma. He discusses the unique immunosensitivity of alveolar soft part sarcoma, the potential of combining checkpoint inhibitors with anti-angiogenic or anti-CTLA-4 agents, and encouraging results with TCR-T cell therapy in synovial sarcoma and myxoid liposarcoma. The role of biomarkers such as tertiary lymphoid structures (TLS) is also highlighted as a predictor of response to immunotherapy.